Invests in categories: BioTechDevelopmentDrugHealthcareHealthTechMedTechPlatformProductResearchTechnology
Early stage venture firm focused on life science discoveries to prevent, detect and cure disease.
News
153
Portfolio
229
Persons
28
Mentions
249
Location: United States, Illinois, Chicago
Employees: 11-50
Founded date: 1986
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B; Series C; Series D; Series F; IPO; Grant
Portfolio 229
| Date | Name | Website | Total Raised | Location |
| 21.08.2026 | Astromech | astromech.com | $20M | - |
| 12.07.2026 | Oratomic | oratomic.com | $300M | United Sta... |
| 26.06.2026 | Trase | trase.ai | $107M | United Sta... |
| 11.06.2026 | Prometheus | prometheus.ai | $12B | United Sta... |
| 10.06.2026 | SonoThera,... | sonothera.com | $310.75M | United Sta... |
| 28.05.2026 | Countable ... | countablelabs.com | $26M | United Sta... |
| 14.05.2026 | CREATE Med... | createmedicines.com | $122M | United Sta... |
| 15.04.2026 | Lightcast | lightcast.bio | $76M | England |
| 02.03.2026 | Salma Heal... | salmahealth.com | $80M | United Sta... |
| 08.01.2026 | Parabilis ... | parabilis.com | $305M | United Sta... |
| 10.11.2025 | Colossal B... | colossal.com | $805M | United Sta... |
| 15.10.2025 | Pelage Pha... | pelagepharma.com | $150.8M | United Sta... |
| 17.05.2025 | Kardigan | kardigan.bio | $300M | United Sta... |
| 17.05.2025 | RhyGaze AG | rhygaze.com | $94.27M | Switzerlan... |
| 17.05.2025 | nChroma Bi... | nchromabio.com | - | United Sta... |
| 17.05.2025 | Tenvie | tenvie.com | $200M | United Sta... |
| 29.12.2024 | Arsenal Bi... | arsenalbio.com | $410M | United Sta... |
| 29.12.2024 | Parabilis ... | parabilismed.com | - | United Sta... |
| 29.12.2024 | City Thera... | citytx.com | $234.5M | United Sta... |
| 29.12.2024 | Vesalius T... | vesaliustx.com | $75M | United Sta... |
| 29.12.2024 | Moleculent... | moleculent.com | $46M | Sweden |
| 16.09.2024 | Mirador Th... | miradortx.com | $250M | United Sta... |
| 16.09.2024 | Metsera | metsera.com | $505M | United Sta... |
| 16.09.2024 | Seaport Th... | seaporttx.com | $325M | United Sta... |
| 16.09.2024 | Xaira Ther... | xaira.com | $1B | United Sta... |
| 16.09.2024 | Gate Biosc... | gatebio.com | $60M | United Sta... |
| 16.09.2024 | Enumerix | enumerix.com | - | United Sta... |
| 09.03.2024 | Moonwalk B... | moonwalk.bio | $127M | United Sta... |
| 09.03.2024 | Basking Bi... | baskingbiosciences.com | $60.4M | United Sta... |
| 09.02.2024 | Lifordi Im... | lifordi.com | $112M | United Sta... |
| 08.11.2023 | SciNeuro P... | scineuro.com | $53M | United Sta... |
| 08.11.2023 | Areteia Th... | areteiatx.com | $425M | United Sta... |
| 08.11.2023 | Ingredient... | ingredientwerks.com | - | United Sta... |
| 08.11.2023 | Paradigm | paradigm.inc | $281M | United Sta... |
| 08.11.2023 | Earth Opti... | earthoptics.com | $61.9M | United Sta... |
| 08.11.2023 | Rippl Care | ripplcare.com | $58M | United Sta... |
| 08.11.2023 | Akamis Bio | akamisbio.com | $60M | - |
| 08.11.2023 | Dispatch B... | dispatchbio.com | $216M | United Sta... |
| 08.11.2023 | Be Biophar... | be.bio | $212M | United Sta... |
| 08.11.2023 | Singleron | singleronbio.com | $100M | China, Jia... |
| 08.11.2023 | Skylark Bi... | skylarkbio.com | - | United Sta... |
| 08.11.2023 | Vilya | vilyatx.com | $121M | United Sta... |
| 08.11.2023 | Pheast The... | pheast.com | $76M | United Sta... |
| 08.11.2023 | Pretzel Th... | pretzeltx.com | $72.5M | United Sta... |
| 08.11.2023 | Synchron | synchron.com | $350M | United Sta... |
| 08.11.2023 | Aera Thera... | aeratx.com | $193M | United Sta... |
| 08.11.2023 | Qihan Biot... | qihanbio.com | $25.5M | China, Zhe... |
| 08.11.2023 | Rapport Th... | rapportrx.com | $324M | United Sta... |
| 08.11.2023 | SonoThera | sonotherabio.com | - | United Sta... |
| 08.11.2023 | 3EO Health | 3eohealth.com | - | United Sta... |
| 08.11.2023 | Accompany ... | accompanyhealth.com | $56M | United Sta... |
| 08.11.2023 | Scale Bios... | scale.bio | - | United Sta... |
| 08.11.2023 | Protillion... | protillion.com | $18M | - |
| 08.11.2023 | Chroma Med... | chromamedicine.com | $260M | United Sta... |
| 08.11.2023 | Matter Neu... | matter.xyz | $26M | - |
| 08.11.2023 | Happy Heal... | happyring.com | $60M | United Sta... |
| 08.11.2023 | Genuity Sc... | genuitysci.com | - | United Sta... |
| 08.11.2023 | Sunbird Bi... | sunbirdbio.com | $14M | United Sta... |
| 08.11.2023 | Magnet Bio... | magnetbio.com | $50M | United Sta... |
| 08.11.2023 | Curie.Bio | curie.bio | - | Canada, On... |
| 08.11.2023 | Elephas Bi... | elephas.com | $136.5M | United Sta... |
| 08.11.2023 | FogPharma | fogpharma.com | $496M | United Sta... |
| 18.05.2023 | Myeloid Th... | myeloidtx.com | $123M | United Sta... |
| 18.05.2023 | OncoRespon... | oncoresponse.com | $27M | United Sta... |
| 26.04.2023 | Orbital Th... | orbitaltx.com | $270M | United Sta... |
| 07.03.2023 | Volastra T... | volastratx.com | $116M | United Sta... |
| 06.02.2023 | Slingshot ... | slingshotbio.com | $34M | United Sta... |
| 27.01.2023 | Paradigm C... | paradigm-research.com | $203M | United Sta... |
| 09.08.2022 | ISCO | iscointl.com | - | United Sta... |
| 03.08.2022 | Homeward | homewardhealth.com | $70M | United Sta... |
| 26.03.2022 | Remix Ther... | remixtx.com | $211M | United Sta... |
| 26.03.2022 | Sesh | seshtherapy.com | $3M | United Sta... |
| 26.03.2022 | Lightcast ... | lightcastd.com | - | United Kin... |
| 26.03.2022 | Altos Labs | altoslabs.com | - | - |
| 26.03.2022 | Kisbee The... | kisbeetx.com | - | United Sta... |
| 26.03.2022 | ImmuneID | immuneidrx.com | $50M | United Sta... |
| 26.03.2022 | Quantum Ci... | quantumcircuits.com | $78M | United Sta... |
| 26.03.2022 | Jaguar Gen... | jaguargenetherapy.com | - | United Sta... |
| 26.03.2022 | Slingshot ... | slingshot.bio | - | United Sta... |
| 26.03.2022 | Treeline B... | treeline.bio | - | United Sta... |
| 26.03.2022 | Tome Biosc... | tome.bio | $213M | United Sta... |
| 26.03.2022 | Generate B... | generatebiomedicines.com | - | United Sta... |
| 26.03.2022 | hC Bioscie... | hcbioscience.com | - | United Sta... |
| 26.03.2022 | PsiOxus Th... | psioxus.com | $75.6M | United Kin... |
| 26.03.2022 | Trotana, I... | trotana.com | - | United Sta... |
| 21.01.2022 | ONI | oni.bio | $75M | United Kin... |
| 07.10.2021 | Neumora | neumoratx.com | $612M | United Sta... |
| 25.08.2021 | Recuro_Hea... | recurohealth.com | $62M | United Sta... |
| 17.07.2021 | AbbVie | abbvie.com | - | United Sta... |
| 17.07.2021 | GenVec | genvec.com | - | United Sta... |
| 17.07.2021 | EMCORE Cor... | emcore.com | - | United Sta... |
| 17.07.2021 | Illumina | illumina.com | $500K | Japan, Min... |
| 17.07.2021 | Crystal IS | asahi-kasei.co.jp | - | United Sta... |
| 17.07.2021 | Codiak Bio... | codiakbio.com | $300M | United Sta... |
| 17.07.2021 | Apex Neuro... | apexneuro.com | - | United Sta... |
| 17.07.2021 | DuPont | dupont.com | - | United Sta... |
| 17.07.2021 | Feelmore L... | feelmorelabs.com | - | United Sta... |
| 17.07.2021 | HiberCell | hibercell.com | $128.15M | United Sta... |
| 17.07.2021 | Feelmore L... | feelcove.com | - | United Sta... |
| 17.07.2021 | Mozart The... | mozart-tx.com | $80M | United Sta... |
Show more
Persons 28
| Date | First Name | Last Name | Title | Location | |||
| - | Kristina | Burow | Managing D... | linkedin.c... | - | - | - |
| - | Mary | Chamberlai... | Venture Pa... | - | - | - | |
| - | Richard | Heyman, Ph... | Venture Pa... | - | - | - | |
| - | Jay | Parrish, P... | Venture Pa... | linkedin.c... | - | - | - |
| - | George | Scangos, P... | Venture Pa... | - | - | - | |
| - | David | Moore | Senior Par... | linkedin.c... | - | - | - |
| - | Axel | Bouchon, P... | Venture Pa... | - | - | - | |
| - | Su | Fu | Affiliate | linkedin.c... | - | - | - |
| - | Joseph | Jeong, Ph.... | Venture Pa... | linkedin.c... | - | - | - |
| - | Paul | Thurk | Managing D... | - | - | - | |
| - | Vicki | Sato, Ph.D... | Venture Pa... | - | - | - | |
| - | Keith | Crandell | Co-founder... | - | - | - | |
| - | Paul | Berns | Managing D... | - | - | - | |
| - | Nilay | Thakar, Ph... | Principal | linkedin.c... | - | - | - |
| - | Clinton | Bybee | Co-founder... | linkedin.c... | - | - | - |
| - | Luciana | Borio, M.D... | Venture Pa... | - | - | - | |
| - | Jason | Doren | General Co... | linkedin.c... | - | - | - |
| - | Robert | Nelsen | Co-founder... | - | - | - | |
| - | Ari | Nowacek, M... | Partner | - | - | - | |
| - | Inca | Coman, Ph.... | Venture Pa... | linkedin.c... | - | - | - |
| - | Carol | Suh | Partner | linkedin.c... | - | - | - |
| - | Corey | Ritter | Partner | linkedin.c... | - | - | - |
| - | Peter | Mintun, Ph... | Associate | - | - | - | |
| - | Mayu | Yoshikawa,... | Venture Pa... | - | - | - | |
| - | Steve | Lazarus | Co-Founder... | - | - | - | |
| - | Kevin | Hrusovsky | Venture Pa... | - | - | - | |
| - | Steve | Gillis, Ph... | Managing D... | linkedin.c... | - | - | - |
| - | Mark | McDonnell | Managing D... | - | - | - |
Show more
News 153
Show more
Mentions in press and media 249
| Date | Title | Description |
| 09.09.2026 | Encoded Therapeutics Inks $275 Million in Series F | SOUTH SAN FRANCISCO, CA, Encoded Therapeutics, a clinical-stage biotechnology company, announced the close of a $275 million financing. >> Click here for more funding data on Encoded Therapeutics >> To export Encoded Therapeuti... |
| 08.09.2026 | Moonwalk Biosciences Grabs $70M Series B | SOUTH SAN FRANCISCO, CA, Moonwalk Biosciences today announced the closing of an oversubscribed $70 million Series B financing. >> Click here for more funding data on Moonwalk Biosciences >> To export Moonwalk Biosciences fundin... |
| 25.08.2026 | LifeMine Therapeutics Secures Landmark Funding, Reshaping Transplant Medicine | LifeMine Therapeutics secured $263 million. This landmark funding fuels a revolution in organ transplant medicine. The company's lead asset, LIFE-001, offers a next-generation approach. It targets rejection without severe toxicities. Tradit... |
| 25.08.2026 | Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners | BEIJING, Aug. 25, 2026 /PRNewswire/ -- On August 25, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Sentivera, a new US venture found... |
| 25.08.2026 | Happy Health Raises $75M in Series A Funding | Happy Health, an Austin, Texas-based digital health and continuous remote monitoring company, raised $75m in Series A funding. The round was co-led by ARCH Venture Partners and OpenLoop. The company will use the capital to fund the commerci... |
| 24.08.2026 | Astromech Secures $20 Million to Pioneer Predictive AI Biology, Valued at $3.8 Billion | Astromech, a cutting-edge computational biology firm, recently secured $20 million in funding. This capital injection propels its mission: to forecast biological evolution using advanced AI. The company aims to predict how living systems ch... |
| 21.08.2026 | Astromech Raises $20 Million To Build AI Biology That Forecasts Evolutionary Changes | For most of science, biology has been reactive. A disease first emerges before a genome sequence follows. A species is first lost before there’s an extinction study. Astromech raises $20 million to train AI models that can predict how livin... |
| 21.08.2026 | Astromech Raises $20M in Funding | Astromech, a Dallas, TX-based computational biology and predictive artificial intelligence startup spun out from de-extinction company Colossal Biosciences, raised $20m in funding. The round was led by Bob Nelsen (co-founder of ARCH Venture... |
| 19.08.2026 | LifeMine Therapeutics Secures $263M Series D & E | WATERTOWN, MA, LifeMine Therapeutics, a clinical-stage biopharmaceutical company, announced $263 million in financing. >> Click here for more funding data on LifeMine Therapeutics >> To export LifeMine Therapeutics funding data... |
| 07.08.2026 | LifeMine Therapeutics Raises $263M in Funding | LifeMine Therapeutics Inc., a Watertown, MA-based clinical-stage biopharmaceutical company leveraging digital genomics research technology, has raised $263M in funding. The round included a $188M Series E financing led by Milky Way Investme... |
| 14.07.2026 | Venture capital & startup funding roundup, July 14, 2026: Blackstone, General Catalyst, Index Ventures, Kleiner Perkins, Lightspeed, & Sequoia | It’s Tuesday, July 14, 2026, and the flow of capital today underscores familiar but intensifying trends: governments and venture firms are doubling down on AI infrastructure and sovereignty, as well as defense and related automation. In the... |
| 13.07.2026 | Oratomic Secures $300M Series A for Fault-Tolerant Quantum Computing | Oratomic, a Pasadena-based quantum computing innovator, recently closed a landmark $300 million Series A funding round. This significant capital injection fuels their mission to build a fault-tolerant, utility-scale neutral-atom quantum com... |
| 13.07.2026 | Venture capital & startup funding roundup, July 13, 2026: Accel, General Catalyst, Sequoia, Intel Capital, Khosla Ventures, and Nvidia Ventures | It’s Monday, July 13, 2026. The past 24 hours of venture news point to a clear focus on compute sovereignty, defense-edge technologies, and the continued ripple effects of the AI arms race. Investors are plowing capital into ventures that p... |
| 13.07.2026 | Oratomic Snares $300 Million Series A | PASADENA, CA, Quantum computer startup, Oratomic, has raised a $300 million Series A financing round. >> Click here for more funding data on Oratomic >> To export Oratomic funding data to PDF and Excel, click here According to ... |
| 12.07.2026 | Стартап Oratomic привлек $300 млн на рекордный квантовый компьютер из 20 тыс. кубитов | Стартап Oratomic закрыл раунд серии A на $300 млн для разработки квантового компьютера промышленного масштаба, который, по расчетам компании, потребует всего 10–20 тыс. кубитов — на порядки меньше, чем закладывают конкуренты. Magnific Раунд... |
| 11.07.2026 | Oratomic Raises $300 Million Series A To Build Fault‑Tolerant Neutral‑Atom Quantum Computers Straight To ‘Endgame’ | Oratomic, a Pasadena‑based quantum computing startup founded by leading neutral‑atom and fault‑tolerant quantum researchers, has raised a $300 million Series A round to accelerate development of a utility‑scale, fault‑tolerant quantum compu... |
| 07.07.2026 | Oratomic Raises $300M in Series A Funding | Oratomic, a Pasadena, CA-based developer of fault-tolerant quantum computing architectures and quantum-error correction systems, raised $300m in Series A funding. The round was co-led by ARCH Venture Partners, Spark Capital, and Khosla Vent... |
| 02.07.2026 | Trase Secures $107M, Igniting AI Revolution for Regulated Industries | Trase raised $107 million in seed funding, led by ARCH Venture Partners. The company delivers an agentic AI operating system, Trase Origin, for highly regulated sectors. This platform deploys specialized AI agents. They automate complex, hi... |
| 26.06.2026 | Trase Raises $107M in Seed Funding | Trase, a McLean, Virginia-based developer of an agentic operating system and artificial intelligence agents for high-stakes environments, raised $107m in seed funding. The round was led by ARCH Venture Partners, with participation from Red ... |
| 25.06.2026 | Ollin Biosciences Raises $330 Million Series B To Advance OLN324 | Ollin Biosciences announced that it raised an oversubscribed $330 million Series B financing round. The round was co-led by new investor TCGX and founding investor ARCH Venture Partners. Participants included a16z Bio+Health, Blackstone Mul... |
| 25.06.2026 | Trase Raises $107 Million Seed Round Led By ARCH Venture Partners | Trase announced it raised a $107 million seed funding round to continue building its agentic operating system for regulated industries. The round was led by ARCH Venture Partners, with participation from Red Cell Partners and other investor... |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 15.06.2026 | Bezos's AI Empire Soars: Prometheus Hits $41 Billion, Robotics Arm Generalist AI Grows | Jeff Bezos's AI ventures boom. Prometheus, his AI startup, secured $12 billion in funding, reaching a $41 billion valuation. It focuses on AI for physical product design and manufacturing. Generalist AI, another Bezos-backed firm, now stand... |
| 12.06.2026 | Jeff Bezos-backed AI startup Prometheus hits $41 billion valuation after $12 billion funding round; details here | Prometheus, an artificial intelligence (AI) startup led by Amazon.com Inc founder Jeff Bezos, has secured a massive funding round, valuing the company at $41 billion. The mega venture firmly establishes the billionaire as a dominant force i... |
| 12.06.2026 | Prometheus Raises $12 Billion at Approx. $41 Billion Valuation | Prometheus, a San Francisco, CA-based developer of physical artificial intelligence and autonomous engineering systems, raised $12 billion in a funding round at an approximately $41 billion valuation. The round was backed by Jeff Bezos, JPM... |
| 11.06.2026 | Jeff Bezos’ Prometheus raises $12B to accelerate industrial engineering projects | Prometheus Inc., an artificial intelligence startup co-led by Amazon.com Inc. founder Jeff Bezos, has raised $12 billion in funding. Axios reported today that the Series B round values the company at $41 billion. The round included contribu... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding. The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 09.06.2026 | City Therapeutics Raises $99.5M in Series B Funding | City Therapeutics, Inc., a Cambridge, MA-based biopharmaceutical company developing RNA interference (RNAi)-based medicines, raised $99.5M in Series B funding. The round was led by Viking Global Investors and Sofinnova Investments with part... |
| 01.06.2026 | Countable Labs Secures $26M to Advance Precision Genomics with Countable PCR | Countable Labs just raised $26 million. This oversubscribed funding round accelerates commercialization of its Countable PCR technology. The platform offers single-molecule quantification, outperforming digital PCR in sensitivity and precis... |
| 28.05.2026 | Countable Labs Raises $26 Million To Accelerate Countable PCR Commercialization | Countable Labs announced it has raised $26 million in an oversubscribed financing round to accelerate clinical product development and global commercialization of its Countable PCR technology. The financing round was led by ARCH Venture Par... |
| 28.05.2026 | Countable Labs Raises $26M in Funding | Countable Labs, the Palo Alto, Ca-based developer of Countable PCR, a single-molecule PCR technology, raised $26M in funding. The round was led by ARCH Venture Partners with participation from F-Prime Capital and Primer Ventures. The compan... |
| 14.05.2026 | Create Medicines Raises $122M in Series B Funding | Create Medicines, Inc., a Cambridge, Massachusetts-based developer of in vivo immune programming and mRNA-LNP cell therapies, raised $122m in Series B funding. The round was co-led by existing investors Newpath Partners, ARCH Venture Partne... |
| 30.04.2026 | Moleculent: $20 Million Raised To Scale Functional Profiling Platform For Cell-Cell Communication Research | Moleculent, a Stockholm-based life sciences technology company pioneering functional profiling to map cell-cell communication at scale in human tissue, has closed a $20 million financing round led by Rubicon Healthcare Partners, with partic... |
| 21.04.2026 | Lightcast Secures Major Funding, Redefines Single-Cell Analysis with Envisia Platform | Lightcast, a life science innovator, secured $27 million in funding. ARCH Venture Partners led the round. This capital fuels the 2026 commercial launch of its Envisia™ benchtop platform. Envisia marks a significant leap in single-cell analy... |
| 15.04.2026 | Lightcast Raises $27M in Funding | Lightcast, a Cambridge, UK-based life science tools company focused on functional single-cell analysis, raised $27M in funding. The round was led by ARCH Venture Partners with participation from M Ventures, Illumina Ventures, +ND Capital, L... |
| 14.04.2026 | Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform | · Proceeds will help enhance workflows and expand single-cell functional assay portfolio · Brad Crutchfield joins as advisor to support early access growth and global launch CAMBRIDGE, England – April 14, 2026 – Lightcast, a pioneering life... |
| 02.03.2026 | Salma Health: $80 Million Series A Raised To Launch Integrated Brain Health Centers Of Excellence | Salma Health has officially emerged from stealth with $80 million in Series A funding to launch an integrated brain health company designed to unify diagnostics, rapid-acting treatments, and coordinated care under one roof. The round was co... |
| 16.02.2026 | IBJ Podcast: Here’s how BiomEdit raised $18.4M in a tough VC year | - |
| 01.02.2026 | Focus on biopharma comes at the right time: Industry | - |
| 14.01.2026 | Mirador Therapeutics Secures $250M, Accelerates Precision Medicine | Mirador Therapeutics secured $250M in Series B funding. This propels their innovative precision medicine strategy. Total capital raised now exceeds $650M. The San Diego firm targets immune-mediated inflammatory and fibrotic diseases. Funds ... |
| 14.01.2026 | Biotech Innovator bit.bio Secures $50M to Revolutionize Drug Discovery | bit.bio, a pioneering UK biotech, has secured $50 million in Series C funding, led by M&G Investments. This significant capital infusion will supercharge its human cell programming technology. The company aims to accelerate drug discove... |
| 13.01.2026 | Mirador Raises $250M in Series B Funding | Mirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding. Backers included T. Rowe Price Investme... |
| 12.01.2026 | Mirador Therapeutics: $250 Million Series B Raised And Multi-Asset Immuno-Fibrotic Pipeline Advanced | Mirador Therapeutics announced it is advancing multiple clinical-stage programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis, with more than 10 clinical readouts expected by the end of ... |
| 11.01.2026 | Vizgen Secures $48 Million to Accelerate Spatial Multi-Omics Expansion | Vizgen, a spatial multi-omics pioneer, secured $48 million. This financing is substantial. It marks a pivotal moment for the Waltham, Massachusetts-based company. The capital fuels aggressive global expansion. It scales vital manufacturing ... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 11.01.2026 | bit.bio Raises $50 Million Series C Led by M&G To Scale Human Cell Programming Platform | M&G Investments has led a $50 million Series C funding round for bit.bio, a Cambridge-based biotechnology company developing human cell programming technology to improve the speed and predictability of drug discovery and safety testing.... |
| 10.01.2026 | Vizgen: $48 Million Funding Raised To Scale Spatial Multi-Omics Platform | Vizgen, a spatial multi-omics company, announced it has closed a $48 million financing led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors. Vizgen said the proceeds will s... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Vizgen Raises $48M in Funding | Vizgen, a Waltham, MA-based spatial multi-omics company, raised $48M in funding. The round was led by ARCH Venture Partners and M Ventures and Northpond Ventures with participation from existing investors. The company intends to use the fun... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug. The funds come from a smorgasbord of existin... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma... |
| 01.01.2026 | The Longevity Startup That Already Has the Data Altos Labs Is Seeking: Hidden in Plain Sight | While Jeff Bezos and Sam Altman fund billion-dollar moonshots in cellular rejuvenation, one biotechnology company has been quietly treating patients for seven years, accumulating the kind of clinical data that typically takes a decade and h... |
| 16.11.2025 | Gate Bioscience: $65 Million Series B Closed To Advance Oral Molecular Medicines Into Clinical Trials | Gate Bioscience has closed a $65 million oversubscribed Series B financing round to accelerate the advancement of its emerging class of oral small-molecule medicines, known as molecular gates. The round brings the company’s total capital ra... |
| 13.11.2025 | Gate Bioscience Raises $65M in Series B Financing | Gate Bioscience, a Brisbane, California-based biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, closed a $65m Series B financing. The round was led by new ... |
| 10.11.2025 | Inside Colossal Biosciences: Interview with CEO & Co-Founder Ben Lamm | Colossal Biosciences is a company leading the field of de-extinction and advanced genetic engineering. Utilizing a sophisticated platform built on CRISPR technology, synthetic biology, and artificial intelligence, Colossal’s primary goal is... |
| 08.11.2025 | Synchron Secures $200 Million to Advance Non-Surgical Brain Interface | Synchron has raised a substantial $200 million in Series D funding. This capital injection propels its Stentrode brain-computer interface platform. The company aims for commercialization and next-generation neural technology. It seeks to re... |
| 07.11.2025 | Elephas Biosciences: $40 Million Series B-2 Raised To Advance Commercialization Of Live Tumor Profiling Platform | Elephas Biosciences has secured $40 million in Series B-2 financing to support the launch and commercialization of its Elephas Live Platform, a laboratory-developed test expected to be introduced in 2026. The company, based in Madison, Wisc... |
| 06.11.2025 | Synchron: $200 Million Series D Closed To Advance Commercial Brain-Computer Interface Platform | Synchron has raised a $200 million Series D financing round to accelerate the commercialization of its Stentrode brain-computer interface platform and advance the development of a next-generation neural interface system. The round was led b... |
| 06.11.2025 | Synchron Raises $200M in Series D Funding | Synchron, a NYC-based which specializes in non-surgical brain-computer interface (BCI) technology, raised $200M in Series D funding. The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Be... |
| 06.11.2025 | Elephas Biosciences Raises $40M in Series B-2 Funding | Elephas Biosciences, a Madison, WI-based private company that has developed a live tumor profiling platform for immunotherapy response prediction, raised $40M in Series B-2 funding. Backers included Northpond Ventures, ARCH Venture Partners... |
| 20.10.2025 | Kardigan: $254 Million Series B Closed To Advance Late-Stage Portfolio Of Personalized Cardiovascular Medicines | Kardigan, a biotechnology company focused on redefining cardiovascular drug development, announced the successful closing of a $254 million Series B financing round. The funding round featured participation from new investors, including Fid... |
| 16.10.2025 | Pelage Pharmaceuticals: $120 Million Series B Raised For Advancing Regenerative Medicine Hair Loss Treatment | Pelage Pharmaceuticals, a Los Angeles–based biotechnology company developing regenerative treatments for hair loss, announced the close of a $120 million Series B financing round co-led by ARCH Venture Partners and GV (Google Ventures). The... |
| 15.10.2025 | Kardigan: $254 Million Series B Secured To Advance Late-Stage Cardiovascular Medicines | Kardigan, a biotechnology company focused on modernizing cardiovascular drug development, announced it has raised $254 million in a Series B funding round to accelerate its late-stage portfolio of personalized medicines targeting heart dise... |
| 15.10.2025 | Pelage Pharmaceuticals Raises $120M in Series B Financing | Pelage Pharmaceuticals, a Los Angeles, CA-based clinical-stage regenerative medicine biotechnology company, closed a $120m Series B financing. The round was co-led by ARCH Venture Partners and GV (Google Ventures), with participation from e... |
| 15.10.2025 | Kardigan Raises $254M in Series B Funding | Kardigan, a South San Francisco, CA- and Princeton, New Jersey-based heart health company modernizing cardiovascular drug development, closed a $254m Series B financing. Backers included Fidelity Management & Research Company, accounts ... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 19.09.2025 | T.Rx Capital: $77.5 Million Fund I Launched To Invest In Startups | T.Rx Capital, a newly formed venture capital firm dedicated to early-stage healthcare innovation, has announced the close of its first fund, T.Rx Capital Fund I, at $77.5 million. The fund is focused on supporting visionary founders who are... |
| 03.09.2025 | Treeline Biosciences: $200 Million Additional Funding Raised And First Clinical Trials Announced | Treeline Biosciences, a company at the forefront of innovative cancer research, recently announced significant progress in its clinical development. They have started Phase 1 trials for three promising programs, two of which are internally ... |
| 05.08.2025 | iBIO Releases Inaugural Member Investor Portfolio Report Showcasing $1.24 Billion in Illinois Life Sciences Investment | Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030 CHICAGO, Aug. 5, 2025 /PRNewswire-PRWeb/ -- The Illinois Biotechnology Innovation Organization (iBIO)... |
| 24.07.2025 | Dispatch Bio Raises Series A in Funding; Total To $216M | Dispatch Bio, a San Francisco, CA- and Philadelphia, PA-based Biotechnology company developing treatments for tumours, raised an undisclosed amounting Series A funding. Backers included ARCH Venture Partners and PICI, along with Bristol Mye... |
| 11.07.2025 | Centivax Secures $45M to Revolutionize Global Immunity | Centivax closed an oversubscribed $45 million Series A funding round. Future Ventures led the investment. This capital fuels the advancement of Centivax’s lead universal flu vaccine candidate. The vaccine will enter Phase I clinical trials ... |
| 10.07.2025 | Centivax: $45 Million Series A Raised For Advancing Universal Flu Vaccine | Centivax, a biotech firm developing vaccines and therapies for long-lasting, universal protection against diverse targets, announced it has closed an oversubscribed $45 million Series A funding round. Steve Jurvetson of Future Ventures led ... |
| 08.07.2025 | NUS Enterprise appoints global innovation experts to advance innovation and research translation efforts | SAN FRANCISCO, July 8, 2025 /PRNewswire/ -- NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS), has appointed Dr Patrick Ennis and Ms Donna See as strategic advisors to support its next phase of growth in ... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D CHICAGO–(BUSINESS WIRE)–May 14, 2025– Top decision-makers from across the biopharma ecosystem will con... |
| 08.05.2025 | Atlas: $155 Million Seed Financing And Acquisition Of Assets From Twist Bioscience | Atlas Data Storage – a technology company building end-to-end DNA data storage – announced the closing of a $155 million seed financing and the acquisition of technology assets from Twist Bioscience. The seed funding investors are ARCH Vent... |
| 06.05.2025 | The Future of Data Storage: Atlas Data Storage's Bold Leap into DNA Technology | In the world of technology, innovation is the lifeblood that fuels progress. Atlas Data Storage, a fledgling company based in South San Francisco, has just secured a staggering $155 million in seed funding. This financial boost marks a sign... |
| 05.05.2025 | Atlas Data Storage Raises $155M in Seed Funding | Atlas Data Storage, a South San Francisco, CA-based technology company building end-to-end DNA data storage solutions, raised $155m in seed financing. Backers included ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capi... |
| 31.03.2025 | Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development | 3 Shares Email Facebook Twitter LinkedIn Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply artificial intelligence to the drug development process. The new round was led by ... |
| 23.01.2025 | MGX’s AI Role In The US Grows | 2 Shares Email Facebook Twitter LinkedIn While most of the talk about the White House’s new Stargate Project centered on the three big tech names — OpenAI, SoftBank and Oracle — Abu Dhabi-based investment firm MGX also is poised to play a b... |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases | RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 15.01.2025 | Colossal Raises $200M in Series C Funding | Colossal Biosciences, a Dallas, TX-based de-extinction company, raised $200M in Series C Funding. Backers included TWG Global. Other investors included USIT, Animal Capital, Breyer Capital, At One Ventures, In-Q-Tel, BOLD Capital, Peak 6, D... |
| 15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
| 13.01.2025 | RhyGaze Closes USD 86M Series A Funding | RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding. The round was led by GV (Google Ventures), alongside Arch Venture Partners, ... |
| 13.01.2025 | RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases | RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-... |
| 08.01.2025 | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing By ReutersJanuary 7, 202511:00 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The Nasdaq logo is displayed at the Nasdaq Mark... |
| 19.12.2024 | bit.bio raises $30 Million led by M&G Investments | bit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets. Jonathan Milner appointed Interim CEO; Mark Kotter assumes Vice Chairman role as Company expands Board with d... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector. Concurrent with the merger, nChr... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 22.11.2024 | Metsera: $215 Million (Series B) Raised To Develop Medicines For Obesity And Metabolic Diseases | Metsera – a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases – announced the closing of a $215 million Series B funding round to further advance its portfolio of highl... |
| 14.11.2024 | Metsera Raises $215M in Series B Financing | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $215M in Series B funding. The round was led by Wellington Management and Venrock, with participation from Fidelity Management and Research Company, Janus Henderson Inves... |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 22.10.2024 | Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines | Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a... |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 09.10.2024 | Rippl: Virtual Dementia Care Company Raises $23 Million (Series A) | Rippl, a leader in virtual dementia care, announced the closing of its Series A funding round. Tina Hoang-To (Kin Ventures Founding General Partner) led the $23 million round with participation from Rippl’s seed investors ARCH Venture Partn... |
| 02.10.2024 | Rippl Secures $23M to Expand its Virtual Dementia Care Platform | What You Should Know: – Rippl, a provider of virtual dementia care raises $23M ina Series A funding round led by Tina Hoang-To, Founding General Partner at Kin Ventures, with participation from existing investors including ARCH Venture Part... |
Show more